Chronic non-cancer pain in adolescents: a narrative review

Abstract Introduction Chronic pain is defined as a pain lasting more than 3-6 months. It is estimated that 25% of the pediatric population may experience some kind of pain in this context. Adolescence, corresponding to a particular period of development, seems to present the ideal territory for the appearance of maladaptive mechanisms that can trigger episodes of persistent or recurrent pain. Methods A narrative review, in the PubMed/Medline database, in order to synthetize the available evidence in the approach to chronic pain in adolescents, highlighting its etiology, pathophysiology, diagnosis, and treatment. Results Pain is seen as a result from the interaction of biological, psychological, individual, social, and environmental factors. Headache, abdominal pain, and musculoskeletal pain are frequent causes of chronic pain in adolescents. Pain not only has implications on adolescents, but also on family, society, and how they interact. It has implications on daily activities, physical capacity, school performance, and sleep, and is associated with psychiatric comorbidities, such as anxiety and depression. The therapeutic approach of pain must be multimodal and multidisciplinary, involving adolescents, their families, and environment, using pharmacological and non-pharmacological strategies. Discussion and conclusion The acknowledgment, prevention, diagnosis, and treatment of chronic pain in adolescent patients seem not to be ideal. The development of evidence-based forms of treatment, and the training of health professionals at all levels of care are essential for the diagnosis, treatment, and early referral of these patients.

Avaliação do manejo médico no atendimento de cefaleia na sala de urgência e emergência do Hospital Regional de Barbacena - MG / Evaluation of medical management in the treatment of headache in the urgency and emergency room of the Hospital Regional de Barbacena - MG

Introdução: O manejo da cefaleia nas salas de urgência e emergência deve ser baseada em uma anamnese detalhada para que o diagnóstico e tratamento sejam adequados, entretanto não é o que se encontra nos atendimentos. Objetivo: Avaliar o manejo do atendimento das cefaleias em uma sala de Urgência e Emergência. Métodos: Estudo de corte transversal retrospectivo, realizado através da análise de dados de 1317 prontuários eletrônicos de pacientes com queixa de cefaleia que procuraram o serviço de emergência do Hospital Regional de Barbacena durante o período de 01 de janeiro de 2017 a 30 de junho de 2019. Os diagnósticos relatados nos prontuários foram classificados de acordo com os critérios da Classificação Internacional das Cefaleias (ICHD-3). Os dados foram submetidos à análise estatísticas, pelo teste de qui-quadrado. Considerou-se diferenças estatisticamente significativas aquelas cujo valor p≤0,05. Resultados: Do total de prontuários, três foram excluídos, sendo analisados 1314. Entre os prontuários analisados, 73,21% apresentaram diagnósticos iniciais eram cefaleia, 16,67% migrânea e 10,12% cefaleia do tipo tensão. Já no diagnóstico final, cefaleia correspondeu a 59,67%, migrânea a 17,95% e cefaleia do tipo tensão a 8,52%. Em relação ao tratamento, foi receitado opioides para 43,99% dos pacientes e para o restante foram prescritos medicamentos não opioides. Conclusão: O trabalho sugeriu falha no manejo da cefaleia nas salas de urgência e emergência, provavelmente pela limitação do conhecimento dos profissionais de saúde acerca da dor de cabeça. O que acarretou no grande número de diagnósticos inespecíficos e inadequada abordagem terapêutica.

Introduction: Detailed clinical evaluation should be the basis for the proper management of headaches in emergency rooms, in order to allow adequate diagnosis and treatment. However, this is not usually observed on clinical rounds. Objective: To evaluate the management of headache consultations in an emergency rooms. Methods: This is a cross-section study was performed analyzing data from 1,317 electronic medical records of patients with headache complaints who sought treatment at the Barbacena City Regional Hospital's between January 1, 2017, and June 20, 2019. Medical records were classified according to the International Classification of Headache Disorders (ICHD-3). The data collected were statistically analyzed using chi-square tests. The study considered a p-value≤0.05 to define statistically significant differences. Results: Three medical records were excluded and 1,314 were analyzed. Among the medical records analyzed, 73.21% of initial diagnoses were classified as headache, 16.67% as migraine, and 10.12% as tension-type headache. Headache corresponded to 59.76% of final diagnoses, migraine to 17.95%, and tension-type headache to 8.52%. Regarding the treatment, 43.99% of patients were prescribed opioids for the remaining were prescribed nonopioid medications. Conclusion: The study suggests that the management of headaches is inadequate in emergency rooms, probably due to limited knowledge of health professionals about headache. This resulted in a large number of nonspecific diagnoses and inadequate therapeutic approaches.

Experiencia en la práctica clínica real de la efectividad y la tolerabi- lidad de tapentadol de liberación prolongada para el tratamiento de dolor crónico postraumático producido por accidentes de trabajo / Real-world clinical practice experience of the effectiveness and tolerability of pro- longed-release tapentadol for the treatment of chronic post-traumatic pain caused by occupational accidents

Se llevó a cabo un estudio observacional para analizar si tapentadol de liberación prolongada (LP) puede considerarse un tratamiento de primera línea para pacientes con dolor crónico postraumático (DCPT). Métodos: Se presenta una serie de casos de la práctica clínica real de pacientes con DCPT producido por accidentes de trabajo. Antes de ingresar al estudio, todos los pacientes recibían tramadol, que se interrumpió cuando se inició la administración de tapentadol LP. Las evaluaciones de dolor incluyeron una escala de valoración numérica, el cuestionario DN4 y la escala de Impresión Global de Cambio del Paciente (PGIC, Patients' Global Impression of Change). Se recuperaron y registraron los eventos adversos. Resultados: 94 pacientes participaron en el estudio y 77 (82 %) completaron todas las visitas predefinidas. Cerca de la mitad de los pacientes informaron dolor crónico que tenía una duración de al menos 3 años; se observó un componente neuropático en el 87 % de los pacientes. El puntaje de dolor se redujo en 1,5 puntos luego del primer mes de tratamiento con tapentadol LP y en 2,48 puntos luego de 4 meses (p<0,05). También se asoció la administración de tapentadol LP con una reducción del 28,9 % de la dosis concomitante de pregabalina (p<0,01). De acuerdo con el cuestionario PGIC, el 74 % y el 77,9 % de los pacientes informó mejoría luego de uno y cuatro meses de tratamiento, respectivamente. El perfil de seguridad fue consistente con los datos actuales sobre tapentadol LP. Conclusión: El dolor osteomuscular crónico es una enfermedad prevalente que se caracteriza por tener resultados terapéuticos deficientes y se asocia a una mayor discapacidad y una mala calidad de vida. En este estudio de la práctica clínica real en pacientes que trabajan y que cuentan con un componente de dolor neuropático elevado, se observó que tapentadol LP produce efectos beneficiosos en términos del control del DCPT, y se obtuvieron índices altos de eficacia y seguridad.

An observational study was carried out to analyze whether prolonged-release (PR) tapentadol may be considered a first-line treatment for patients with chronic post-traumatic pain (PTD). Methods: A case series of cases of patients with PTFE caused by work accidents in a real clinical practice setting is described. Before entering the study, all patients were receiving tramadol, which was discontinued when PR tapentadol was started. Pain assessments included a numerical rating scale, the DN4 questionnaire, and the Patients' Global Impression of Change (PGIC) scale. Adverse events were retrieved and described. Results: 94 patients participated in the study and 77 (82%) completed all the predefined visits. About half of the patients reported chronic pain that lasted for at least 3 years. A neuropathic component was reported in 87% of patients. The pain score was reduced by 1.5 points after the first month of treatment with PR tapentadol and by 2.48 points after 4 months (p < 0.05). Administration of PR tapentadol was also associated with a concomitant reduction of pregabalin dose of 28.9% (p < 0.01). According to the PGIC questionnaire, 74% and 77.9% of patients reported improvement after one and four months of treatment, respectively. The safety profile was consistent with current data on PR tapentadol. Conclusion: Chronic musculoskeletal pain is a prevalent disease characterized by poor therapeutic results and associated with increased disability and poor quality of life. In our study in a real clinical practice setting with patients with a high neuropathic pain component, PR tapentadol produced beneficial effects in terms of DCPT control, and high efficacy and safety rates were obtained. Keywords: tapentadol, chronic pain, pain caused by work accidents, chronic post-traumatic pain, evidence from real clinical practice.

Artroplastía total de rodilla con asistencia de brazo-robótico: resultados clínicos postoperatorios tempranos / Robotic arm-assisted total knee arthroplasty: early postoperative results

OBJETIVO: Describir los resultados clínicos postoperatorios tempranos de la primera serie de pacientes operados de artroplastía total de rodilla (ATR) con asistencia de brazo-robótico en Latinoamérica. MATERIALES Y MÉTODOS: Estudio prospectivo de 52 pacientes (53 rodillas) con gonartoris tricompartimental sintomática operados de ATR primaria con asistencia de brazo-robótico (RIO-MAKO) de manera consecutiva, con seguimiento a 2 meses postoperados. No se excluyeron pacientes. Se utilizó el mismo protocolo anestésico y de rehabilitación. Se realizó revisión de fichas clínicas para recolectar los siguientes resultados: tiempo de isquemia quirúrgica, estadía hospitalaria, tiempo a marcha, dolor postoperatorio diario [Escala visual análoga (EVA)], uso de opioides, rangos de movilidad articular (ROM), pérdida sanguínea, complicaciones y eje mecánico postoperatorio. RESULTADOS: Tiempos de Isquemia: 82 minutos (60­120). Estadía Hospitalaria: 4 días (2­12). Dolor postoperatorio: EVA el mismo día operatorio de 0 (0­10) y previa al alta de 0 (rango 0­4), con 0,3 purgas (0­6,5) de opioides por paciente. Tiempo a marcha (día logrado): 1 día (1­3), cuarenta y cinco pacientes (84,9%) iniciaron la marcha el primer día postoperatorio. ROM (Extensión-Flexión): Aumento progresivo durante el seguimiento. En el control ambulatorio de los dos primeros meses [23 días (13­50)], veintiún pacientes (40%) alcanzaron un ROM mayor o igual a 0­90° y once (20%) presentaron un ROM funcional máximo (0­120°). Pérdida sanguínea: Siete pacientes (13,2%) requirieron transfusión. Complicaciones: un paciente (1,89%) presentó una dehiscencia del cierre de la artrotomía. No hubo otras complicaciones. Eje mecánico postoperatorio: 179,1° (178,2­180). DISCUSIÓN: Los resultados concuerdan con la evidencia descrita en otras regiones, sugiriendo que la asistencia de brazo-robótico permite resultados postquirúrgicos reproducibles. CONCLUSIÓN: Los resultados clínicos postoperatorios tempranos de esta serie de pacientes operados de ATR con asistencia de brazo-robótico, muestran una baja percepción del dolor, con bajo consumo de opioides, una rápida recuperación funcional de la marcha y ROM, y excelentes resultados desde el punto de vista del eje mecánico postoperatorio. NIVEL DE EVIDENCIA: IV.

OBJECTIVE: Describe the early clinical postoperative outcomes, of the first series of patients operated on Robotic Arm-Assisted Total Knee Arthroplasty (TKA) in Latin America. MATERIAL AND METHOD: Retrospective study including 52 patients (53 knees) with advanced symptomatic knee osteoarthritis, consecutively operated on Robotic ArmAssisted TKA (RIO-MAKO) during October 2018 and May 2019 with two months of follow-up. No patients were excluded from the study. The same anesthetic and rehabilitation protocol was followed for all patients. Data were obtained from the clinical files for the following outcomes: Surgical tourniquet time, hospital stay, time to walk, postoperative daily pain [Visual Analog Scale (VAS)], opioid consumption, range of motion (ROM), blood loss, complications, and the attained postoperative mechanical axis. RESULTS: Tourniquet Time: 82 minutes (60­120). Hospital Stay: 4 days (2­12). Postoperative Pain: VAS of 0 (0­10) the same day of surgery, and 0 (0­4) before discharge. The opioid consumption was 0,3 purge (0­6,5) per patient. Time to Walk (Day achieved): 1st day (1­3), forty-five patients (84,9%) walked on their first postoperative day. ROM (Extension-Flexion): progressively increases during the follow up. On the first two-month visits [23 days (13­50)], twenty-one patients (40%) reached a ROM equal or superior to 0­90°, and eleven (20%) presented a maximal functional ROM (0­120°). Blood Loss: Seven patients (13.2%) required a blood transfusion. Complications: one patient (1.89%) presented dehiscence of the arthrotomy closure. No other complications were registered. Postoperative Mechanical Axis: 179.1° (178.2­180). DISCUSSION: The results coincide with the reported evidence from other regions. Robotic-arm assistance may generate reproducible postoperative results. CONCLUSIONS: The early postoperative clinical results of this series of patients operated on Robotic Arm-Assisted TKA show a low pain perception and opioid use, a rapid functional rehabilitation in terms of gait and ROM, and excellent postoperative mechanical alignment. LEVEL OF EVIDENCE: IV.

A national study on the use of opioid analgesics in dentistry

Abstract The aim of this study was to assess the frequency of opioid analgesics prescribed by Brazilian dentists, potential regional differences and their association with socioeconomic and health-related factors. Data for all opioid prescriptions by dentists was obtained from the 2012 database of the National Controlled Substances Management System, regulated by the Brazilian Health Surveillance Agency. The number of defined daily doses (DDD) and DDDs per 1,000 inhabitants per day for each Brazilian state were calculated as the primary outcomes. DDDs were compared by regions and Brazilian states. Spearman's rho correlation coefficient was used to determine the influence of the states' characteristics, such as the Human Development Index; poverty; education; number of dentists per 100,000 inhabitants; visit to the dentist; dental care plan; good or very good oral health; number of pharmaceutical establishments per 100,000/inhabitants; and ability to get all prescribed medications. Data analysis was performed using IBM SPSS Statistics 25.0. A total of 141,161 prescriptions for opioids analgesics by 36,929 dentists were recorded, corresponding to 658,855 doses of opioids dispensed in 2012. The most commonly dispensed opioids were codeine associated with paracetamol (83.2%; n = 117,493). The national DDDs per 1,000 inhabitants per day was 0.0093 (range: 0.0002-0.0216). DDD per 1,000 inhabitants per day was positively associated to visits to dentists (rs = 0.630; P < 0.001) and inversely associated to poverty (rs = -0.624; p = 0.001). There are significant differences in opioid prescriptions in dentistry among the Brazilian states. These differences may be associated with non-clinical factors.

Influence of tramadol on functional recovery of acute spinal cord injury in rats

Abstract Purpose: To evaluate the influence tramadol on functional recovery of acute spinal cord injury in rats. Methods: Ten rats were divided into two groups (n = 5). All animals were submitted by a laminectomy and spinal cord injury at eighth thoracic vertebra. In control group, the rats didn't receive any analgesic. In tramadol group, the rats received tramadol 4mg/Kg at 12/12h until 5 days by subcutaneous. Animals were following by fourteen days. Was evaluated the Basso, Beattie, Bresnahan scale (locomotor evaluation) and Rat Grimace Scale (pain evaluation) at four periods. Results: There no difference between the groups in locomotor evaluation in all periods evaluated (p>0.05) and in both groups there was a partial recover of function. The tramadol group show a lower pain levels at the first, third and seventh postoperatively days when comparing to the control group. Conclusion: The tramadol as an analgesic agent don't influence on functional recovery of acute spinal cord injury in rats

Subcostal transversus abdominis plane block can improve analgesia after laparoscopic cholecystectomy / O bloqueio do plano transverso abdominal subcostal pode melhorar a analgesia após colecistectomia laparoscópica

Abstract Background and goal of study: After laparoscopic cholecystectomy, patients have moderate pain in the early postoperative period. Some studies shown beneficial effects of subcostal transversus abdominis plane block on reducing this pain. Our goal was to investigate influence of subcostal transversus abdominis plane block on postoperative pain scores and opioid consumption. Materials and methods: We have randomized 76 patients undergoing laparoscopic cholecystectomy to receive either subcostal transversus abdominis plane block (n = 38) or standard postoperative analgesia (n = 38). First group received bilateral ultrasound guided subcostal transversus abdominis plane block with 20 mL of 0.33% bupivacaine per side before operation and tramadol 1 mg.kg−1 IV for pain breakthrough (≥6). Second group received after operation tramadol 1 mg.kg−1/6 h as standard hospital analgesia protocol. Both groups received acetaminophen 1 g/8 h IV and metamizole 2.5 g/12 h. Pain at rest was recorded for each patient using NR scale (0-10) in period of 10 min, 30 min, 2 h, 4 h, 8 h, 12 h and 16 h after the surgery. Results and discussion: We obtained no difference between groups according age, weight, intraoperative fentanyl consumption and duration of surgery. Subcostal transversus abdominis plane block significantly reduced postoperative pain scores compared to standard analgesia in all periods after surgery. Tramadol consumption was significantly lower in the subcostal transversus abdominis plane (24.29 ± 47.54 g) than in the standard analgesia group (270.2 ± 81.9 g) (p = 0.000). Conclusion: Our results show that subcostal transversus abdominis plane block can provide superior postoperative analgesia and reduction in opioid requirements after laparoscopic cholecystectomy.

Resumo Justificativa e objetivo: Após a colecistectomia laparoscópica, os pacientes apresentam dor moderada no pós-operatório imediato. Alguns estudos mostraram efeitos benéficos do bloqueio do plano transverso abdominal subcostal na redução dessa dor. Nosso objetivo foi investigar a influência do bloqueio do plano transverso abdominal subcostal nos escores de dor no pós-operatório e no consumo de opioides. Materiais e métodos: Foram randomizados 76 pacientes submetidos à colecistectomia laparoscópica para receber o bloqueio do plano transverso abdominal subcostal (n = 38) ou analgesia padrão no pós-operatório (n = 38). O primeiro grupo recebeu bloqueio do plano transverso abdominal subcostal bilateral guiado por ultrassom com 20 mL de bupivacaína a 0,33% em cada lado antes da operação e tramadol IV (1 mg.kg−1) para controle da dor (≥ 6). O segundo grupo recebeu tramadol (1 mg.kg−1/6 h) como protocolo-padrão de analgesia hospitalar pós-cirurgia. Ambos os grupos receberam acetaminofeno IV (1 g/8 h) e dipirona (2,5 g/12 h). A dor em repouso foi registrada para cada paciente com o uso da escala NR (0-10) nos períodos de 10 min, 30 min, 2 h, 4 h, 8 h, 12 h e 16 h após a cirurgia. Resultados e discussão: Não houve diferença entre os grupos em relação a idade, peso, consumo intraoperatório de fentanil e duração da cirurgia. O bloqueio do plano transverso abdominal subcostal reduziu significativamente o escore de dor no pós-operatório em comparação com a analgesia-padrão em todos os períodos após a cirurgia. O consumo de tramadol foi significativamente menor no grupo bloqueio do plano transverso abdominal subcostal (24,29 ± 47,54 g) do que no grupo analgesia padrão (270,2 ± 81,9 g) (p = 0,000). Conclusão: Nossos resultados mostram que o bloqueio do plano transverso abdominal subcostal pode proporcionar analgesia superior no pós-operatório e redução da necessidade de opioides após colecistectomia laparoscópica.

Comparison of two combinations of opioid and non-opioid analgesics for acute periradicular abscess: a randomized clinical trial

Abstract Acute periradicular abscess is a condition characterized by the formation and propagation of pus in the periapical tissues and generally associated with debilitating pain. Objective: The aim of this study was to compare the overall analgesic effectiveness of two combinations of opioid and non-opioid analgesics for acute periradicular abscess. Material and Methods: This study included 26 patients who sought emergency care in a Brazilian dental school. The patients were randomly divided into two groups: Co/Ac - oral prescription of codeine (30 mg) plus acetaminophen (500 mg), every 4 h, for 3 days or Tr/Ac - oral prescription of tramadol hydrochloride (37.5 mg) plus acetaminophen (500 mg) on the same schedule. Two factors were evaluated: (1) pain scores recorded by the patients in a pain diary 6, 12, 24, 48, and 72 h after treatment, using the Visual Analogue Scale; and (2) the occurrence of adverse effects. Results: In both groups, there was a reduction in pain scores over time. For the Co/Ac group, there was a significant reduction in the scores 12, 24, 48, and 72 hours after treatment (P<0.05). In the Tr/Ac group, the scores significantly decreased over time from time point 6 h (P<0.05). Comparing the pain at each time point, the groups were not significantly different (P>0.05), i.e., both treatments were effective in controlling pain caused by APA; however, the combination of Tr/Ac caused more adverse reactions as two patients had to stop using the medication. Conclusion: This study suggests that, considering both analgesic efficacy and safety, the combination of codeine and acetaminophen is more effective to control moderate to severe pain from acute periradicular abscesses.

Acupuncture and pharmacopuncture are as effective as morphine or carprofen for postoperative analgesia in bitches undergoing ovariohysterectomy

ABSTRACT PURPOSE : To investigate the analgesic effect of acupuncture (AP) or micro-dose pharmacopuncture (PA), using carprofen or morphine, in bitches undergoing ovariohysterectomy (OHE). METHODS: Thirty five dogs were randomly assigned to five groups after sedation with acepromazine IM: AP, 0.5 mg.kg-1 of morphine subcutaneously (SC), 4 mg.kg-1 of carprofen SC, and PA with 0.05 mg.kg-1 of morphine or 0.4 mg.kg-1 of carprofen. Anaesthesia was induced with propofol and maintained with isoflurane. Pain was assessed after OHE by a blind observer for 24h, by dynamic visual analogue scale (DIVAS), Glasgow (CMPS-SF), Melbourne (UMPS) and Colorado University pain scale (CSU). Animals reaching 33% of the UMPS score received rescue analgesia with morphine IM. Non parametric data were analysed by Kruskal-Wallis or Friedman tests where applicable, followed by Dunn´s test. Parametric data were analysed by two way ANOVA, followed by Tukey test. RESULTS: There were no differences among groups in number of rescue analgesia. Except for the DIVAS score where animals treated with morphine had the lowest score compared with AP and carprofen, at 1h after surgery, there were no other differences among groups. CONCLUSION: Acupuncture or pharmacopuncture were equally effective as morphine or carprofen to control postoperative pain in bitches undergoing ovariohysterectomy.

Programas de monitoreo de medicamentos de prescripción en los Estados Unidos de América / Prescription drug monitoring programs in the United States of America

Desde finales de la década de los años noventa, el número de muertes por sobredosis que involucran analgésicos opioides se ha cuadriplicado en los Estados Unidos de América (de 4 030 muertes en 1999 a 16 651 en 2010). Los objetivos de este artículo son proporcionar una visión general del problema de sobredosis de medicamentos de prescripción en los Estados Unidos y discutir las acciones que podrían ayudar a reducir el problema, abordando en forma directa las características de los Programas de monitoreo de medicamentos de prescripción (PDMP). Estos programas están compuestos de bases de datos a nivel estatal que vigilan las sustancias controladas. La información recopilada en las bases de datos está a disposición de las personas autorizadas por el Estado (por ejemplo, los médicos, los farmacéuticos y otros proveedores de cuidado médico) y debe ser utilizada solo con propósitos profesionales. Los proveedores pueden utilizar dicha información para evitar la interacción con otros medicamentos, la duplicación terapéutica o la identificación de conductas de búsqueda de drogas. Las agencias del orden público pueden utilizar estos programas para identificar patrones de prescripción inadecuada, dispensación o desviación.

Since the late 1990s, the number of opioid analgesic overdose deaths has quadrupled in the United States of America (from 4 030 deaths in 1999 to 16 651 in 2010). The objectives of this article are to provide an overview of the problem of prescription drug overdose in the United States and to discuss actions that could help reduce the problem, with particular attention to the characteristics of prescription drug monitoring programs (PDMPs). These programs consist of state-level databases that monitor controlled substances. The information compiled in the databases is at the disposal of authorized persons (e.g., physicians, pharmacists, and other health-care providers) and may be used only for professional purposes. Suppliers can use such information to prevent interaction with other drugs or therapeutic duplication, or to identify drug-search behavior. Law enforcement agencies can use these programs to identify improper drug prescription or dispensing patterns, or drug diversion.

Morphine as first medication for treatment of cancer pain / Morfina como primeiro medicamento para tratamento da dor de câncer / Morfina como primer medicamento para el tratamiento del dolor de cáncer

BACKGROUND AND OBJECTIVES: the medications used according to the recommendation of the World Health Organization do not promote pain relief in a number of patients with cancer pain. The aim of this study was to evaluate the use of morphine as first medication for the treatment of moderate cancer pain in patients with advanced and/or metastatic disease, as an option to the recommendations of the World Health Organization analgesic ladder. METHOD: sixty patients without opioid therapy, with >18 years of age, were randomized into two groups. G1 patients received medication according to the analgesic ladder and started treatment with non-opioids in the first, weak opioids in the second, and strong opioids in the third step; G2 patients received morphine as first analgesic medication. The efficacy and tolerability of initial use of morphine were evaluated every two weeks for three months. RESULTS: the groups were similar with respect to demographic data. There was no significant difference between the groups regarding pain intensity, quality of life, physical capacity, satisfaction with treatment, need for complementation and dose of morphine. In G1 there was a higher incidence of nausea (p = 0.0088), drowsiness (p = 0.0005), constipation (p = 0.0071) and dizziness (p = 0.0376) in the second visit and drowsiness (p = 0.05) in the third. CONCLUSIONS: the use of morphine as first medication for pain treatment did not promote better analgesic effect than the ladder recommended by World Health Organization, with higher incidence of adverse effects. .

JUSTIFICATIVA E OBJETIVOS: Os medicamentos usados segundo a recomendação da Organização Mundial de Saúde (OMS) não promovem alívio da dor de uma parcela dos pacientes com dor oncológica. O objetivo deste estudo foi avaliar o uso de morfina como primeiro medicamento para o tratamento da dor oncológica moderada, em pacientes com doença avançada e/ou metástases, como opção às recomendações da escada analgésica preconizada pela OMS. MÉTODO: Sessenta pacientes sem terapia com opioide, com idade maior ou igual a 18 anos, foram distribuídos aleatoriamente em dois grupos. Os pacientes do G1 receberam medicamentos segundo a escada analgésica e iniciaram o tratamento com não opioide no primeiro degrau, opioide fraco no segundo e opioide potente no terceiro; os do G2 receberam morfina como primeiro medicamento analgésico. Foram avaliadas a eficácia e a tolerabilidade do uso inicial de morfina, a cada duas semanas durante três meses. RESULTADOS: Os grupos foram semelhantes quanto aos dados demográficos. Não houve diferença significante entre os grupos quanto à intensidade da dor, qualidade de vida, capacidade física, satisfação com o tratamento, necessidade de complementação e dose de morfina usada. No G1 houve maior incidência de náusea (p = 0,0088), sonolência (p = 0,0005), constipação (p = 0,0071) e tontura (p = 0,0376) na segunda consulta e para sonolência (p = 0,05) na terceira. CONCLUSÕES: O uso de morfina como primeiro medicamento para tratamento da dor não promoveu melhor efeito analgésico do que a escada preconizada pela OMS e houve maior incidência de efeitos adversos. .

JUSTIFICACIÓN Y OBJETIVOS: los medicamentos usados según la recomendación de la Organización Mundial de la Salud (OMS) no generan alivio del dolor de un grupo de pacientes con dolor oncológico. El objetivo de este estudio fue evaluar el uso de la morfina como primer medicamento para el tratamiento del dolor oncológico moderado en pacientes con enfermedad avanzada y/o metástasis, como opción a las recomendaciones de la escala analgésica preconizada por la OMS. MÉTODO: sesenta pacientes sin terapia con opiáceos, con una edad mayor o igual a los 18 años, fueron distribuidos aleatoriamente en 2 grupos. Los pacientes del G1 recibieron medicamentos según la escala analgésica iniciando el tratamiento con no opiáceo en la primera etapa, opiáceo débil en la segunda y opiáceo potente en la tercera; los del G2 recibieron morfina como primer medicamento analgésico. Fueron evaluadas la eficacia y la tolerabilidad del uso inicial de la morfina cada 2 semanas durante 3 meses. RESULTADOS: los grupos fueron similares en cuanto a los datos demográficos. No hubo diferencia significativa entre los grupos en lo que respecta a la intensidad del dolor, calidad de vida, capacidad física, satisfacción con el tratamiento, necesidad de complementación y dosis de morfina usada. En el G1 hubo una mayor incidencia de náuseas (p = 0,0088), somnolencia (p = 0,0005), estreñimiento (p = 0,0071) y mareos (p = 0,0376) en la segunda consulta, y de somnolencia (p = 0,05) en la tercera. CONCLUSIONES: el uso de la morfina como primer medicamento para el tratamiento del dolor no generó un efecto analgésico mejor que la escala preconizada por la OMS, habiendo una mayor incidencia de efectos adversos. .

Methadone in post-herpetic neuralgia: A pilot proof-of-concept study

OBJECTIVE: This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens. METHODS: This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699 RESULTS: Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments. Conclusions: Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic ...

Dolor perdurable II. Tratamiento / [Enduring pain II. Treatment].

Pain disorders present highly challenging therapeutic problems, owing in part to complex co-morbidities associated with pain disorders, notably including psychiatric disorders characterized by depressed mood or anxiety. Many treatments are employed to treat pain-disorder patients, and most are unsatisfactory. Virtually all analgesic medicines in long-term use provide only partial efficacy and present substantial risks of adverse effects, loss of benefit over time, or dependency and risk of abuse. Commonly employed drugs with analgesic properties include non-opioids (mainly nonsteroidal anti-inflammatory agents [NSAIDs] or acetaminophen), many natural or synthetic opioids (including opiates and phenylpiperidines), some antidepressants (especially those with noradrenergic activity), a few anticonvulsants, skeletal muscle relaxants or topical remedies, and a growing variety of experimental treatments. The major overlap between pain and psychiatric disorders, as well as the currently unsatisfactory state of treatments available for chronic pain syndromes, encourage a comprehensive approach to assessment and clinical management of patients with chronic pain. Many current treatment programs for pain disorder patients offer narrowly specialized and incomplete treatment options. Ideally however, such care should be provided by multi-disciplinary teams with expertise in neurology, general medicine, pain management, physical medicine and rehabilitation, as well as psychiatry. Psychiatrists as well as pain specialists can serve an essential role in leading comprehensive assessment and general management of such complex and challenging patients who are typically only partially responsive to available treatments.

Trends and characteristics of pethidine use in Taiwan: a six-year-long survey

OBJECTIVES: To investigate the trends and characteristics of pethidine prescriptions and users in Taiwan from 2002 to 2007. METHOD: All pethidine users (n = 3,301,136) in Taiwan from 2002 to 2007 were linked to National Health Insurance claims to identify pethidine prescriptions. We examined the trends in pethidine user prevalence and the proportion of pethidine prescriptions according to health care characteristics. A logistic regression model was used to compare patient demographics and health care characteristics associated with pethidine prescriptions between 2002 and 2007. RESULTS: Despite the decline in the number of pethidine users and prescriptions over the six-year period, more than half a million people were prescribed pethidine annually. In fact, an increasing proportion of pethidine prescriptions were observed in clinics, outpatient settings, and patients who had both operations and cancer diagnoses. Pethidine prescriptions were mostly associated with a non-operation status without a cancer diagnosis (>60%). However, approximately 10% of the total pethidine prescriptions were found in patients with a cancer diagnosis but no operation. Compared to those in 2002, pethidine prescriptions in 2007 were more likely to be found in people 80 years or older, rural residents, patients from clinics, outpatient settings and operation patients with cancer diagnoses. CONCLUSIONS: A population-based survey in Taiwan demonstrated decreasing consumption of pethidine from 2002 to 2007; however, an increased proportion of prescriptions in certain health care settings was observed. In addition, 10% of the pethidine prescriptions were for cancer patients without operations. These cases need further evaluation for the determination of appropriate pethidine use.

Electroacupuncture versus morphine for the postoperative control pain in dogs / Eletroacupuntura versus morfina para o controle da dor pós-operatória em cães

PROPOSE: To compare the postoperative analgesic effects of electroacupuncture, morphine or sham acupuncture in dogs undergoing mastectomy. METHODS: Thirty client-owed dogs undergoing to mastectomy were randomly assigned to three groups of 10 animals each and received either morphine (T-M), the electroacupuncture (T-EA) or sham procedure (T-Sham). Pre-anesthetic medication was acepromazine (0.05 mg kg-1, IM). Anesthesia was induced with propofol (4 to 5 mg kg-1, IV) and maintained with isoflurane. Postoperatively pain degree was assessed using a numerical rating scale. Dogs were scored at 1, 3, 6 and 12 hours post-extubation. If the pain score was ≥6, supplemental morphine was administered. Serum cortisol concentration was measured before pre-anesthetic medication, at 45 minutes after the anesthetic induction, and at 1, 3 and 6 hours post-extubation. RESULTS: The pain score did not differ among the treatments, but rescue analgesia was lower in the T-EA group (2 of 10 dogs), when compared with T-Sham (6 of 10 dogs) and T-M (6 of 10 dogs) groups. Serum cortisol concentration did not differ among the treatments. CONCLUSION: Electroacupuncture reduces the postoperative analgesic requirement and promotes satisfactory analgesia in dogs undergoing mastectomy.

OBJETIVO: Comparar o efeito analgésico pós-operatório mediado pela aplicação de morfina, eletroacupuntura ou pontos falsos de acupuntura em cadelas submetidas à mastectomia. MÉTODOS: Trinta cadelas encaminhadas para mastectomia foram aleatoriamente distribuídas em três grupos de dez animais cada, sendo tratadas com morfina (T-M), eletroacupuntura (T-EA) ou pontos falsos de acupuntura (T-sham). A medicação pré-anestésica (MPA) foi realizada com acepromazina (0,05 mg kg-1, IM), seguindo-se a indução e manutenção anestésica com propofol (4 a 5 mg kg-1, IV) e isofluorano, respectivamente. O grau de analgesia foi avaliado 1, 3, 6 e 12 horas após a extubação traqueal, empregandose a escala descritiva numérica. Animais, cujos escores foram ≥6 receberam analgesia de resgate com morfina (0,5 mg kg-1, IM). A concentração sérica de cortisol foi avaliada antes da MPA, aos 45 minutos após a indução anestésica e 1, 3 e 6 horas após a extubação traqueal. RESULTADOS: O escore de dor não variou entre os tratamentos, porém a analgesia resgate foi menos frequente no T-EA (2 de 10 animais), em relação ao T-sham (6 de 10 animais) e ao T-M (6 de 10 animais). CONCLUSÃO: A eletroacupuntura reduz o requerimento analgésico pós-operatório e confere analgesia satisfatória em cadelas submetidas à mastectomia.

Síndrome dolorosa pós-laminectomia: estudo descritivo da abordagem terapêutica em 56 pacientes / Failed back surgery pain syndrome: therapeutic approach descriptive study in 56 patients

OBJETIVO: Os autores apresentam os resultados da avaliação clínica e acompanhamento de 56 pacientes com diagnóstico de síndrome dolorosa pós-laminectomia lombar. MÉTODOS: Estudo descritivo, prospectivo realizado no período de um ano. Neste estudo foram avaliados 56 pacientes caracterizados com síndrome dolorosa pós-laminectomia lombar em nossa instituição. As idades variaram de 28 a 76 anos (média de 48,8 ± 13,9 anos). Avaliação da dor com Escala Visual e Analógica (EVA). RESULTADOS: A dor pós-operatória foi mais intensa (8,3, média de EVA) que a pré-operatória (7,2). Síndrome dolorosa miofascial (SDM) foi diagnosticada em 85,7 por cento dos pacientes, anormalidades neuropáticas associadas ou não à SDM em 73,3 por cento. O tratamento farmacológico associado à medicina física proporcionou melhora de mais de 50 por cento da dor em 57,2 por cento dos casos, a infiltração dos pontos-gatilho miofasciais em 60,1 por cento e a infusão de morfina com lidocaína no compartimento epidural lombar em 69,3 por cento dos casos refratários. CONCLUSÃO: Nos pacientes com síndrome pós-laminectomia, a dor pós-operatória foi mais intensa que a dor pré-operatória da hérnia de disco. Um componente miofascial foi verificado na maioria dos doentes.

OBJECTIVE: The authors show the clinical evaluation and follow-up results in 56 patients diagnosed with a failed back surgery pain syndrome. METHODS: Descriptive and prospective study conducted over a one-year period. In this study, 56 patients with a failed back surgery pain syndrome were assessed in our facility. The age ranged from 28 to 76 years (mean, 48.8 ± 13.9 years). The pain was assessed through a Visual Analog Scale (VAS). RESULTS: Postoperative pain was more severe (mean VAS score 8.3) than preoperative pain (7.2). Myofascial pain syndromes (MPS) were diagnosed in 85.7 percent of patients; neuropathic abnormalities associated or not with MPS were found in 73.3 percent. Drug therapy associated with physical medicine treatment provided > 50 percent pain improvement in 57.2 percent of cases; trigger point injection in 60.1 percent, and epidural infusion of morphine with lidocaína in 69.3 percent of refractory cases. CONCLUSION: In patients with a post-laminectomy syndrome, postoperative pain was more severe than preoperative pain from a herniated disk. A miofascial component was found in most patients.

Síndrome de dolor regional complejo tipo II: manejo interdisciplinario / Type II complex regional pain syndrome: multidisciplinary approach

El síndrome de dolor regional complejo tipo II o causalgia es un cuadro que se presenta con dolor intenso y síntomas autonómicos importantes, que alteran la calidad de vida de los pacientes. Sus mecanismos fisiopatológicos todavía están en discusión y la evidencia disponible para su manejo aún es escasa. Actualmente, la tendencia es hacia un manejo interdisciplinario que abarque terapias psicológicas, de rehabilitación, en conjunto con un correcto manejo del dolor.

Type II complex regional pain syndrome causes accute pain and autonomous symptoms that alter the patient's quality of life. Discussion with respect to the syndrome physiopathologic mechanisms is still open and available evidence is scarce. The present trend is the multidisciplinary approach with teams using psychological, rehabilitation and pain management therapies.